PinPoint Get PinPoint on the App Store

Peptides / Compound guide

PT-141 guide

PT-141, also called bremelanotide, is a melanocortin receptor agonist studied in women with hypoactive sexual desire disorder.[2] PinPoint uses clinical reference values for its tracking entry while keeping the research-vial package example separate from the approved presentation.[1]

PINPOINT EDITORIAL · UPDATED 05 OCT 2026
FDA-labeled presentation · 2.5 h model input

Editorial still life for peptides research guides

ILLUSTRATION / COMPOUND LIBRARY SERIES

At a glance

PT-141 library factsPeptides. Routes: subcutaneous. Half-life model input: 2.5 hours. Package: 10 mg / package. FDA-labeled presentation. CATEGORYROUTES IN LIBRARYHALF-LIFE MODEL INPUTTYPICAL PACKAGERESEARCH STATUS Peptidessubcutaneous2.5 hours10 mg / packageFDA-labeled presentation SOURCE / PINPOINT COMPOUND LIBRARY

Read the record in context

Two PT-141 numbers need qualification: the library stores 2.5 hours, while its label note describes approximately 2.7 hours. The historical 10 mg supplier vial is an unverified library snapshot. The separately labeled autoinjector below provides a different, verified presentation for the primary arithmetic example.[1]

What the research says

The bremelanotide label describes two controlled phase 3 studies in premenopausal women with acquired, generalized hypoactive sexual desire disorder. Participants received subcutaneous bremelanotide or placebo during a 24-week controlled phase. The research population and indication are narrower than a general claim about sexual function.[2]

The primary assessments used patient-reported measures of desire and associated distress. The studies also collected adverse-event information and included an open-label extension. These clinical assessments are distinct from the pharmacokinetic program, which measured plasma bremelanotide exposure after subcutaneous administration.[2]

The label reports concentration and exposure parameters for its formulated autoinjector product. The research-catalog vial in the library is a separate package record and is not the studied device. Product identity, route, population, and measured endpoint all remain necessary context for reading the bremelanotide evidence.[2][1]

Cited amounts

The Vyleesi label identifies a single-dose autoinjector containing 1.75 mg of bremelanotide in 0.3 mL of prepared solution. This labeled presentation supplies the primary example. The supplier link for the historical library package redirects to sign-in, so that research-vial amount is not used as a verified arithmetic input.[6][1]

Explore the PT-141 dosing chart

Half-life and timing

Using the stored value, five halvings take 12.5 hours. At five hours the mathematical fraction is 25%, and at ten hours it is 6.25%. Repeating the calculation with 2.7 hours instead would move the fifth endpoint to 13.5 hours. That one-hour difference illustrates how the selected scalar affects a graph. Neither version measures an individual's clearance or reproduces absorption, and displaying both does not establish that a supplier formulation matches the labeled product.[1][5]

PT-141: modeled fraction over five half-livesStarting at 100 percent, the model halves each 2.5 hours. After 12.5 hours, 3.125 percent remains. This is arithmetic, not a measured concentration. ELAPSED HOURS / MODELED STARTING AMOUNT 0 h100%2.5 h50%5 h25%7.5 h12.5%10 h6.25%12.5 h3.125% Explore the PT-141 half-life model

Reconstitution

The separately labeled Vyleesi presentation contains 1.75 mg in each autoinjector. Two devices therefore contain 3.5 mg of total inventory. This count calculation does not select an administration amount, a syringe volume, or a frequency. The solution is already supplied in the device, so no water volume is added. The approved label does not verify the historical research-catalog vial retained in the library snapshot.[6]

2 autoinjectors × 1.75 mg = 3.5 mg
Open PT-141 conversion math

Tracking it in PinPoint

From a reference to a record

Built for peptide, TRT, and GLP-1 schedules. Set up your vial in seconds, log every dose, and see your modeled levels between doses. Enter vial size in mg, mcg, or IU and water volume for instant concentration and syringe units. Track vials and prefilled pens side by side.[4]

The Home curve models your levels between doses from published half-life data. Drag to scrub modeled values at any timestamp, or preview 30 days of a dose pattern. Ask PinPoint provides educational reference with sources; it never recommends a dose or a schedule change. These features record and visualize entered information, with the limits of each compound's source data still applying.

Get PinPoint on the App Store

Frequently asked questions

Does a PT-141 calculator reproduce the approved product?
A calculator does not reproduce an approved device. The primary example here simply counts labeled bremelanotide autoinjectors, while the research-catalog amount remains an unverified library snapshot. Arithmetic does not establish formulation equivalence or replace the approved presentation instructions.[1][6]
Why are 2.5 and 2.7 hours both mentioned for PT-141?
The first is the scalar stored by PinPoint; the second is the approximate label reference described in its source note. Stating both avoids attributing an exact 2.5-hour claim to the label while keeping the app's model reproducible.[1][5]
Does the PT-141 vial calculator include the approved device's instructions?
The primary example adds the contents of labeled autoinjectors as inventory. It does not reproduce a device model or select an administration amount. The calculator link remains a separate arithmetic resource; the unavailable supplier listing cannot supply verified preparation inputs.[6][1][5]
Can a peptide tracker app record PT-141?
PinPoint's compound library includes PT-141. The app description covers logging compound, dose, site, and pain level, as well as viewing modeled levels between recorded doses. The curve uses published reference inputs and does not account for individual variation. The tracker records the schedule entered by its user; it does not choose a dose or recommend a schedule change.[1][4]

Sources

Facts and reference links were retrieved from the PinPoint application library on 5 October 2026. Links below preserve the library's citations; a catalog source supports a package amount only. Source references carried from the library have not all been independently reverified. Arithmetic examples are identified separately from clinical evidence.

  1. PinPoint compound library, PT-141Snapshot of the application library; its references and uncertainty are retained below.Retrieved 2026-10-05 · library
  2. DailyMed prescribing informationIdentity and research summary checked against this document on 5 October 2026. Clinical pharmacology and product-description sections.Retrieved 2026-10-05 · library-reference
  3. Supplier catalog package referenceUnverified package locator: the public product link redirects to sign-in. The amount is retained only as a library snapshot in At a glance and does not supply the worked example.Retrieved 2026-10-05 · unverified-supplier
  4. PinPoint App Store descriptionFeature wording from the approved application description, not pricing.Retrieved 2026-10-05 · app-description
  5. Unit conversion and exponential-decay arithmeticC = amount / volume; remaining fraction = 2^(-elapsed / half-life). These are illustrations, not measurements.Retrieved 2026-10-05 · arithmetic
  6. Vyleesi prescribing information: package presentationVerified 5 October 2026, section 16. Separate approved autoinjector presentation; does not validate a research-catalog vial.Retrieved 2026-10-05 · product-label